Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer

被引:2
|
作者
Gao, Yina [1 ]
Dong, Yangyang [1 ]
Zhou, Yingxu [1 ]
Chen, Gongyan [1 ]
Hong, Xuan [1 ]
Zhang, Qingyuan [1 ]
机构
[1] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China
基金
中国国家自然科学基金;
关键词
LYMPH-NODE INVOLVEMENT; SURVIVAL; SURGERY; ETOPOSIDE; RATIO;
D O I
10.1155/2022/4183326
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Small cell lung cancer (SCLC) is an aggressive malignancy. Surgical resection is currently only recommended for clinical stage I patients who have been carefully staged. The clinical outcomes of patients with resected SCLCs vary because the disease is highly heterogeneous, suggesting that selected patients could be considered for surgical resection depending on their clinical and/or molecular characteristics. Methods. We collected data on a retrospective cohort of 119 limited-stage SCLC patients who underwent lobectomy with mediastinal lymph node dissection from March 2013 to March 2020 at Harbin Medical University Cancer Hospital. Correlations were derived using Fisher's exact test. Models of 2-year and 3-year survival were evaluated by deriving the area under receiver operating characteristic curves. Kaplan-Meier and Cox regression analyses were used to evaluate significant differences between the survival curves and hazard ratios. Results. The median disease-free survival (DFS) was 35.9 months (range 0.9-105.3 months), and the median overall survival (OS) was 45.2 months (range 4.8-105.3 months). Univariate analysis showed that TNM stage was significantly correlated with DFS and OS. The 2-year disease-free rates of patients with stage I, II, and III disease were 76.4%, 50.5%, and 36.1%, respectively, and the 3-year OS rates were 75.9%, 57.7%, and 34.4%, respectively. In pN + patients, multiple (or multiple-station) lymph node involvement significantly increased recurrence and reduced survival compared with patients with single or single-station metastases. Patients with peripheral SCLCs evidenced significantly better DFS and OS than did patients with central tumors. Multivariate analysis showed that TNM stage and tumor location were independently prognostic in Chinese patients with resected limited-stage SCLC. A combination of TNM stage and tumor location was helpful for prognosis. Conclusions. TNM stage and tumor location were independently prognostic in Chinese patients with resected SCLCs. Patient stratification by tumor location should inform the therapeutic strategy. The role of surgical resection for limited-stage SCLC patients must be reevaluated, as this may be appropriate for some patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Predicting prognosis of post-chemotherapy patients with resected IIIA non-small cell lung cancer
    Zheng, Difan
    Wang, Yiyang
    Li, Yuan
    Sun, Yihua
    Chen, Haiquan
    JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : 4186 - +
  • [42] Nomogram Predicting the Prognosis of Patients with Surgically Resected Stage IA Non-small Cell Lung Cancer
    Deng, Xu-Feng
    Dai, Yin
    Liu, Xiao-Qing
    Qi, Huang-Zhi
    Zhou, Dong
    Zheng, Hong
    Li, Jiang
    Liu, Quan-Xing
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2023, 14 (02) : 376 - 386
  • [43] Evaluation of arachidonic acid pathways with prognosis in patients with surgically resected non-small cell lung cancer
    Su, Yinghao
    Zhang, Ming-Zhi
    Wen, Wanqing
    Zheng, Wei
    Eisenberg, Rosana
    Massion, Pierre P.
    Cai, Qiuyin
    CANCER RESEARCH, 2015, 75
  • [44] Nomogram Predicting the Prognosis of Patients with Surgically Resected Stage IA Non-small Cell Lung Cancer
    Xu-Feng Deng
    Yin Dai
    Xiao-Qing Liu
    Huang-Zhi Qi
    Dong Zhou
    Hong Zheng
    Jiang Li
    Quan-Xing Liu
    Indian Journal of Surgical Oncology, 2023, 14 : 376 - 386
  • [45] A STUDY OF SURGICALLY RESECTED PERIPHERAL NON-SMALL CELL LUNG CANCER WITH A TUMOR DIAMETER OF 1.0 CM OR LESS
    Baba, T.
    Uramoto, H.
    Kuwata, T.
    Oka, S.
    Shigematsu, Y.
    Nagata, Y.
    Shimokawa, H.
    Takenoyama, M.
    Hanagiri, T.
    Tanaka, F.
    SCANDINAVIAN JOURNAL OF SURGERY, 2011, 100 (03) : 153 - 158
  • [46] Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
    Zhang, Zhihui
    Wu, Peng
    Zhang, Chaoqi
    Luo, Yuejun
    Zhang, Guochao
    Zeng, Qingpeng
    Wang, Lide
    Yang, Zhaoyang
    Sun, Nan
    He, Jie
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [47] Role for adjuvant chemotherapy in patients with resected small cell lung cancer
    Du, Lingling
    Waqar, Saiama N.
    Morgensztern, Daniel
    JOURNAL OF THORACIC DISEASE, 2016, 8 (08) : 1891 - 1892
  • [48] SMOX expression predicts the prognosis of non-small cell lung cancer
    Huang, Zhanghao
    Wang, Shuo
    Zhang, Hai-Jian
    Zhou, You Lang
    Shi, Jia-Hai
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (13)
  • [49] Peripheral Immune Cell Gene Expression Predicts Survival of Patients with Non-Small Cell Lung Cancer
    Kossenkov, Andrew V.
    Dawany, Noor
    Evans, Tracey L.
    Kucharczuk, John C.
    Albelda, Steven M.
    Showe, Louise C.
    Showe, Michael K.
    Vachani, Anil
    PLOS ONE, 2012, 7 (03):
  • [50] Flattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer
    Fang, Luo
    He, Ying
    Tong, Yinghui
    Hu, Luying
    Xin, Wenxiu
    Liu, Yujia
    Zhong, Like
    Zhang, Yiwen
    Huang, Ping
    ONCOTARGET, 2017, 8 (18) : 30092 - 30099